Galapagos, Senexis collaborate on Alzheimer's disease targets

By Angela McDaniels

Seattle, Dec. 2 - Senexis Ltd. and Galapagos NV said they have expanded their collaboration to advance Senexis' small molecule Alzheimer's programs toward clinical trials.

Galapagos will receive research fees for the medicinal chemistry services provided by its BioFocus division to optimize Senexis' inhibitors of amyloid-induced toxicity and neuroinflammation.

"We have now made significant progress with our small molecule program, so that our lead series now demonstrate similar potency to peptides when inhibiting amyloid-induced toxicity," said David Scopes, Senexis chief scientific officer, in a company news release.

Senexis is a drug development company based in Cambridge, England, that develops treatments and diagnostics for major aging-related diseases.

Galapagos is a genomics-based drug discovery company based in Mechelen, Belgium. The BioFocus division provides target-to-drug discovery products and services to pharmaceutical and biotech companies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.